Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

PAPILLON reports longest OS in EGFR ex20ins NSCLC with amivantamab–chemo
08 Oct 2026
bởiAudrey Abella
First-line (1L) amivantamab plus chemotherapy improves overall survival (OS) in patients with treatment-naïve, locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations, according to the results from the protocol-specified final OS analysis of the phase III PAPILLON study.
08 Oct 2026







